国产精品嫩草影院久久,日本中文字幕高清,av狠狠操

Pfizer Secures Global Rights to SSGJ-707: A Next-Gen PD-1/VEGF Bispecific for Cancer Treatment Pfizer Pfizer acquires global rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3SBio, aiming to enhance its oncology pipeline with a novel mechanism and strong clinical potential.
Nuvation Bio's Ibtrozi Gains FDA Nod to Compete in Lung Cancer Market FDA Nuvation Bio’s Ibtrozi (taletrectinib) secures FDA approval for treating ROS1-positive non-small cell lung cancer, offering a next-gen alternative to Pfizer, BMS, and Roche therapies with strong efficacy and CNS safety.
NEJM Study: Exercise Boosts Colon Cancer Survival Comparable to Drugs Cancer A groundbreaking NEJM phase 3 trial confirms structured exercise significantly improves survival and reduces recurrence in colon cancer patients—comparable to some anti-cancer drugs.
ASCO 2025: Opening a New Era of "Cancer Eradication" ASCO Discover the latest breakthroughs from ASCO 2025, including innovative cancer treatments, immunotherapy advances, bispecific antibodies, and promising breast cancer therapies shaping the future of oncology.
ASCO 2025 Colorectal Cancer Highlights: Plenary & Oral Sessions, Breakthrough Treatments & Studies ASCO Discover the latest breakthroughs in colorectal cancer at ASCO 2025, featuring key plenary and oral presentations on innovative treatments like ATOMIC, BREAKWATER, ANCHOR, and KRAS G12C inhibitors. Stay ahead in oncology research.
2025 ASCO: Major Breakthroughs in Gastric Cancer Treatment: Latest Advances Preview ASCO Discover the latest breakthroughs in gastric cancer treatment from the 2025 ASCO Annual Meeting, including immunotherapy, targeted therapies, and CAR-T advances improving survival and hope for patients worldwide.
ASCO 2025: Most-Viewed Abstracts ASCO Discover the top 4 most viewed abstracts at ASCO 2025, including updates on zanidatamab, talazoparib, GFH375, and Ziftomenib across gastric, prostate, solid tumors, and AML research.
ASCO 2025: Top 10 Clinical Breakthrough Oncology Products with Key Trial Results ASCO Discover the top 10 clinical breakthrough oncology products presented at ASCO 2025, featuring innovative therapies from leading companies with promising efficacy and safety data in advanced cancers.
2025 ASCO: Chinese Pharma Innovations in Lung, Gastric, Blood & Thyroid Cancer Treatments ASCO 2025 ASCO abstracts highlight breakthroughs by Chinese pharmaceutical companies across lung, gastric, hematologic, and thyroid cancers, showcasing innovation in targeted and combination therapies.
Revolutionary Development in Cancer Immunotherapy: Pep-TACs Cancer Pep-TACs, a new breakthrough in cancer immunotherapy, offer a novel platform for targeted protein degradation. Unlike traditional technologies, Pep-TACs overcome challenges like drug resistance, tumor penetration, and blood-brain barrier limitations.

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a